Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury: Insights Into the SENECA Trial

Overview

Journal JACC CardioOncol

Specialty Cardiology & Vascular Diseases

Date 2021 Oct 4

PMID 34604804

Citations 32

Authors

Connor G OBrien

Mehmet Ozgun Ozen

Gentaro Ikeda

Evgeniya Vaskova

Ji Hye Jung

Nathan Bayardo

Michelle Rai Santoso

Liye Shi

Christine Wahlquist

Zewen Jiang

Yunshin Jung

Yitian Zeng

Elizabeth Egan

Robert Sinclair

Adrian Gee

Ronald Witteles

Mark Mercola

Katrin J Svensson

Utkan Demirci

Phillip C Yang

Affiliations

Soon will be listed here.

Abstract

Background: Anthracycline-induced cardiomyopathy (AIC) is a significant source of morbidity and mortality in cancer survivors. The role of mesenchymal stem cells (MSCs) in treating AIC was evaluated in the SENECA trial, a Phase 1 National Heart, Lung, and Blood Institute-sponsored study, but the mechanisms underpinning efficacy in human tissue need clarification.

Objectives: The purpose of this study was to perform an in vitro clinical trial evaluating the efficacy and putative mechanisms of SENECA trial-specific MSCs in treating doxorubicin (DOX) injury, using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iCMs) generated from SENECA patients.

Methods: Patient-specific iCMs were injured with 1 μmol/L DOX for 24 hours, treated with extracellular vesicles (EVs) from MSCs by either coculture or direct incubation and then assessed for viability and markers of improved cellular physiology. MSC-derived EVs were separated into large extracellular vesicles (L-EVs) (>200 nm) and small EVs (<220nm) using a novel filtration system.

Results: iCMs cocultured with MSCs in a transwell system demonstrated improved iCM viability and attenuated apoptosis. L-EVs but not small EVs recapitulated this therapeutic effect. L-EVs were found to be enriched in mitochondria, which were shown to be taken up by iCMs. iCMs treated with L-EVs demonstrated improved contractility, reactive oxygen species production, ATP production, and mitochondrial biogenesis. Inhibiting L-EV mitochondrial function with 1-methyl-4-phenylpyridinium attenuated efficacy.

Conclusions: L-EV-mediated mitochondrial transfer mitigates DOX injury in patient-specific iCMs. Although SENECA was not designed to test MSC efficacy, consistent tendencies toward a positive effect were observed across endpoints. Our results suggest a mechanism by which MSCs may improve cardiovascular performance in AIC independent of regeneration, which could inform future trial design evaluating the therapeutic potential of MSCs.

Citing Articles

SHINE: SERS-based Hepatotoxicity detection using Inference from Nanoscale Extracellular vesicle content.

Parlatan U, Boudreau L, Torun H, Fan L, Aygun U, Gokaltun A bioRxiv. 2025; .

PMID: 39974950 PMC: 11838255. DOI: 10.1101/2025.01.30.635446.

Mitochondria-Rich Microvesicles Alleviate CNI ED by Transferring Mitochondria and Suppressing Local Ferroptosis.

Liang Z, Chen Z, Zhang C, Chen C, Yang W, Zhang Y Int J Nanomedicine. 2024; 19:11745-11765.

PMID: 39558916 PMC: 11570538. DOI: 10.2147/IJN.S488163.

Mitochondrial transplantation: a promising strategy for treating degenerative joint diseases.

Luo H, Lai Y, Tang W, Wang G, Shen J, Liu H J Transl Med. 2024; 22(1):941.

PMID: 39407249 PMC: 11475785. DOI: 10.1186/s12967-024-05752-0.

Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases.

Ore A, Angelastro J, Giulivi C Brain Sci. 2024; 14(9).

PMID: 39335395 PMC: 11429837. DOI: 10.3390/brainsci14090899.

Hydrogel Microneedle Patches Loaded with Stem Cell Mitochondria-Enriched Microvesicles Boost the Chronic Wound Healing.

Yao W, Zhou J, Tang C, Zhang J, Chen Z, Li Y ACS Nano. 2024; 18(39):26733-26750.

PMID: 39238258 PMC: 11447894. DOI: 10.1021/acsnano.4c06921.

References

Haraszti R, Didiot M, Sapp E, Leszyk J, Shaffer S, Rockwell H . High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 2016; 5:32570. PMC: 5116062. DOI: 10.3402/jev.v5.32570. View

Patel K, Tredan O, Tannock I . Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol. 2013; 72(1):127-38. DOI: 10.1007/s00280-013-2176-z. View

Zhang Y, Yu Z, Jiang D, Liang X, Liao S, Zhang Z . iPSC-MSCs with High Intrinsic MIRO1 and Sensitivity to TNF-α Yield Efficacious Mitochondrial Transfer to Rescue Anthracycline-Induced Cardiomyopathy. Stem Cell Reports. 2016; 7(4):749-763. PMC: 5063626. DOI: 10.1016/j.stemcr.2016.08.009. View

Bramwell V, Morris D, Ernst D, Hings I, Blackstein M, Venner P . Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res. 2002; 8(2):383-93. View

Liu F, Vermesh O, Mani V, Ge T, Madsen S, Sabour A . The Exosome Total Isolation Chip. ACS Nano. 2017; 11(11):10712-10723. PMC: 5983373. DOI: 10.1021/acsnano.7b04878. View

Santoso M, Ikeda G, Tada Y, Jung J, Vaskova E, Sierra R . Exosomes From Induced Pluripotent Stem Cell-Derived Cardiomyocytes Promote Autophagy for Myocardial Repair. J Am Heart Assoc. 2020; 9(6):e014345. PMC: 7335524. DOI: 10.1161/JAHA.119.014345. View

Ikeda G, Santoso M, Tada Y, Li A, Vaskova E, Jung J . Mitochondria-Rich Extracellular Vesicles From Autologous Stem Cell-Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium. J Am Coll Cardiol. 2021; 77(8):1073-1088. PMC: 8626617. DOI: 10.1016/j.jacc.2020.12.060. View

Hasinoff B, Herman E . Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?. Cardiovasc Toxicol. 2007; 7(2):140-4. DOI: 10.1007/s12012-007-0023-3. View

Burridge P, Li Y, Matsa E, Wu H, Ong S, Sharma A . Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016; 22(5):547-56. PMC: 5086256. DOI: 10.1038/nm.4087. View

10.

Silva Ramos E, Motori E, Bruser C, Kuhl I, Yeroslaviz A, Ruzzenente B . Mitochondrial fusion is required for regulation of mitochondrial DNA replication. PLoS Genet. 2019; 15(6):e1008085. PMC: 6553695. DOI: 10.1371/journal.pgen.1008085. View

11.

Lee A, Inayathullah M, Lijkwan M, Zhao X, Sun W, Park S . Prolonged survival of transplanted stem cells after ischaemic injury via the slow release of pro-survival peptides from a collagen matrix. Nat Biomed Eng. 2018; 2(2):104-113. PMC: 5927627. DOI: 10.1038/s41551-018-0191-4. View

12.

Keizer H, Pinedo H, Schuurhuis G, Joenje H . Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990; 47(2):219-31. DOI: 10.1016/0163-7258(90)90088-j. View

13.

Cleeter M, Cooper J, Schapira A . Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem. 1992; 58(2):786-9. DOI: 10.1111/j.1471-4159.1992.tb09789.x. View

14.

Swenson C, Bolcsak L, Batist G, Guthrie Jr T, Tkaczuk K, Boxenbaum H . Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs. 2003; 14(3):239-46. DOI: 10.1097/00001813-200303000-00008. View

15.

Takemura G, Fujiwara H . Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007; 49(5):330-52. DOI: 10.1016/j.pcad.2006.10.002. View

16.

Liu J, Mao W, Ding B, Liang C . ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 2008; 295(5):H1956-65. PMC: 2614569. DOI: 10.1152/ajpheart.00407.2008. View

17.

Garbade J, Dhein S, Lipinski C, Aupperle H, Arsalan M, Borger M . Bone marrow-derived stem cells attenuate impaired contractility and enhance capillary density in a rabbit model of Doxorubicin-induced failing hearts. J Card Surg. 2009; 24(5):591-9. DOI: 10.1111/j.1540-8191.2009.00844.x. View

18.

Mohammadi Gorji S, Karimpor Malekshah A, Hashemi-Soteh M, Rafiei A, Parivar K, Aghdami N . Effect of mesenchymal stem cells on Doxorubicin-induced fibrosis. Cell J. 2013; 14(2):142-51. PMC: 3584430. View

19.

Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q . Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem. 2009; 285(1):793-804. PMC: 2804228. DOI: 10.1074/jbc.M109.070037. View

20.

Yu Q, Li Q, Na R, Li X, Liu B, Meng L . Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol Cell Biochem. 2013; 387(1-2):279-85. DOI: 10.1007/s11010-013-1894-1. View